Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
economics, econometrics and finance
Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy
European Journal of Health Economics, Volume 12, No. 3, Year 2011
Notification
URL copied to clipboard!
Description
The presence of metabolic syndrome in patients with hypertension significantly increases the risk of cardiovascular disease, type 2 diabetes and mortality. Our aim is to estimate the economic burden to the health service of metabolic syndrome (MetS) in patients with hypertension and its consequences, in three European countries in 2008, and to forecast future economic burden in 2020 using projected demographic estimates and assumptions around the growth of MetS. An age-, sex- and risk group-structured prevalence-based cost of illness model was developed using the United States Adult Treatment Panel III of the National Cholesterol Education Program criteria to define MetS. Data sources included published information and public use databases on disease prevalence, incidence of cardiovascular events, prevalence of type 2 diabetes, treatment patterns and cost of management in Germany, Spain and Italy. The economic burden to the health service of MetS in patients with hypertension has been estimated at 24,427 €, 1,900 € and 4,877 € million in Germany, Spain and Italy, and is forecast to rise by 59, 179 and 157%, respectively, by 2020. The largest components of costs included the management of prevalent type 2 diabetes and incident cardiovascular events. Mean annual costs per hypertensive patient were around three-fold higher in subjects with MetS compared to those without and rose incrementally with the additional number of MetS components present. In conclusion, the presence of MetS in patients with hypertension significantly inflates economic burden, and costs are likely to increase in the future due to an aging population and an increase in the prevalence of components of MetS. © 2010 Springer-Verlag.
Authors & Co-Authors
Wille, Eberhard
Germany, Heidelberg
Universität Heidelberg
Scholze, Juergen E.
Germany, Berlin
Charité – Universitätsmedizin Berlin
Alegria, Eduardo
Spain, Donostia-san Sebastian
Servicio de Cardiología
Ferri, Claudio
Italy, L'aquila
Università Degli Studi Dell'aquila
Langham, Sue
United Kingdom, Manchester
Independent Health Economist
Stevens, Warren
United States, Boston
Independent Health Economist
Jeffries, David J.
Gambia, Banjul
Medical Research Council Laboratories Gambia
Uhl-Hochgraeber, Kerstin
Germany, Berlin
Bayer Pharma ag
Statistics
Citations: 17
Authors: 8
Affiliations: 8
Identifiers
Doi:
10.1007/s10198-010-0223-9
ISSN:
16187598
e-ISSN:
16187601
Research Areas
Health System And Policy
Noncommunicable Diseases
Study Design
Cross Sectional Study
Cohort Study